Meloxicam Tablet
Product Images NDC 72789-402

This is a description of Meloxicam 7.5 mg tablets. The dosage information advises reading the prescribing information. It includes storage instructions to keep the tablets at 20°C to 25°C and in a tight container in a dry place. The medication is to be kept out of the reach of children. The tablets are dispensed with an accompanying medication guide. The pharmaceutical company mentioned is PD-Rx Pharmaceuticals, Inc. with contact information provided. The product information includes a barcode (GTIN), NDC number, expiration date (10/2024), and lot number (G23B46).*

Each tablet contains Meloxicam 15 mg. This medication is manufactured for PD-Rx Pharmaceuticals, Inc. It should be stored at 20° to 26°C (68° to 77°F) and dispensed in a tight container. Keep the tablets in a dry place and out of the reach of children. Always read the accompanying prescribing information and dispense with the accompanying medication guide. The GTIN for this product is 00372789403908.*

This text provides information on the usage of NSAIDs (nonsteroidal anti-inflammatory drugs) and the associated risks. It emphasizes avoiding NSAIDs before or after specific medical procedures like heart surgery. Additionally, it highlights the increased risk of heart attack if NSAIDs are taken following a recent heart attack unless advised otherwise by a healthcare provider.*

This text provides information on potential risks associated with the use of NSAIDs (nonsteroidal anti-inflammatory drugs), such as ulcers or bleeding, which can increase in likelihood with factors like a history of stomach issues, use of certain medications, increasing NSAID doses, smoking, alcohol consumption, older age, poor health, liver disease, or bleeding problems. It suggests being cautious and seeking medical attention if experiencing symptoms that could lead to serious outcomes.*

This text appears to be a list of symptoms related to health concerns. It mentions symptoms such as shortness of breath, slurred speech, chest pain, swelling of the face or throat, and weakness on one side of the body. These symptoms could be indicative of various medical conditions and should be evaluated by a healthcare professional.*

This text provides a list of potential symptoms that may indicate a serious health concern. These symptoms include nausea, fatigue, diarrhea, itching, yellow skin or eyes, stomach pain, flu-like symptoms, vomiting blood, black or tar-like bowel movements, unusual weight gain, skin rash with fever, and swelling in the arms, legs, hands, and feet. It is important to seek medical attention if any of these symptoms are experienced.*

This is a breakdown of adverse events occurring in 22% of patients taking meloxicam in a placebo- and active-controlled trial for osteoarthritis. The table provides percentages for various side effects, such as gastrointestinal issues, abdominal pain, diarrhea, accidents, edema, falls, flu-like symptoms, dizziness, headache, respiratory problems, and skin rashes. This data can be helpful for healthcare professionals in understanding the potential adverse effects of meloxicam treatment.*

Table 1b provides an overview of adverse events occurring in more than 2% of patients treated with Meloxicam in two 12-week placebo-controlled trials for Rheumatoid Arthritis. The table shows the percentage of patients experiencing various adverse events, such as gastrointestinal disorders, musculoskeletal issues, and nervous system disorders. Specific conditions include abdominal pain, dyspeptic signs and symptoms, flu-like illness, joint-related signs, headaches, and skin rashes. The data helps understand the side effects associated with Meloxicam treatment.*

This is a list of potential side effects and adverse reactions associated with a medication. The effects are categorized by the body systems they impact, including Body as a Whole, Cardiovascular, Central and Peripheral Nervous System, Gastrointestinal, Heart Rate and Rhythm, Hematologic, Liver and Biliary System, Metabolic and Dehydration, Nutritional, Psychiatric, Respiratory, Skin and Appendages, Special Senses, and Urinary System. The list includes a range of symptoms and conditions such as allergic reactions, edema, fatigue, hypertension, tremors, gastrointestinal issues, heart rhythm abnormalities, hematologic conditions, liver function abnormalities, metabolic changes, psychiatric symptoms, respiratory issues, skin reactions, visual abnormalities, and urinary system changes.*

This is a table listing adverse events (%) occurring in more than 2% of Meloxicam patients in 4 to 6 weeks and 6-month active-controlled osteoarthritis trials. It provides detailed information on various side effects experienced by patients taking different doses of Meloxicam, such as gastrointestinal issues, abdominal pain, constipation, diarrhea, dizziness, headache, anemia, back pain, insomnia, coughing, urinary tract infections, and more. The data includes the frequency of adverse events for different doses of Meloxicam over different time frames, allowing for a comprehensive comparison of the side effects associated with the medication.*

This text provides important information about the clinical impact and interventions required when using Meloxicam in combination with other medications such as Lithium, Methotrexate, Cyclosporine, NSAIDs, Salicylates, and Pemetrexed. It emphasizes the need for monitoring patients for potential toxicity and advising against certain combinations due to increased risks, especially in cases of renal impairment.*

The provided text discusses clinically significant drug interactions with Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID). It highlights interactions with medications that interfere with hemostasis, such as anticoagulants, antiplatelet agents, and serotonin-reuptake inhibitors, emphasizing the increased risk of bleeding when used together. Additionally, it mentions the impact of combining NSAIDs with analgesic doses of aspirin, which may lead to higher incidence of gastrointestinal adverse reactions. Furthermore, the text touches upon interactions between Meloxicam and ACE inhibitors, angiotensin receptor blockers, or beta-blockers, cautioning about potential diminished antihypertensive effects and the risk of renal function deterioration, especially in elderly or volume-depleted patients. It advises monitoring blood pressure and renal function during concomitant use. Lastly, the text mentions the impact of NSAIDs on the natriuretic effect of diuretics, specifically loop diuretics and thiazide diuretics, suggesting that NSAIDs can reduce the diuretic efficacy by inhibiting renal prostaglandin synthesis. It recommends observing patients for signs of worsening renal function when Meloxicam is used with diuretics. Overall, this text provides essential information on potential drug interactions involving Meloxicam, guiding healthcare professionals on monitoring, interventions, and considerations when combining Meloxicam with other medications.*